All News
Weight Loss as a Therapeutic Goal in Psoriatic Arthritis
Psoriatic arthritis (PsA) is a complex inflammatory disease often complicated by obesity, which not only worsens disease activity but also impairs treatment response. At ACR Convergence 2025, three compelling studies spanning pharmacologic, lifestyle, and longitudinal observational data converged on a central theme: weight loss is a powerful modulator of PsA outcomes, regardless of the intervention used.
Read Article
#ACR25 Clinical Preview by Prof Coates for use now:
GLP-1 agonist & Diet
Abstr#813 GIP/GLP-1 improved MSK pain
Abstr#849 GLP-1 reduced risk of #MACE in PsA
Abstr#2690 RCT = the degree of weight loss regardless specific dietary strategy determined benefit in PsA @RheumNow https://t.co/4jB0fFHosC
Links:
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Does diet matter in PsA?
Randomized study comparing advice, DASH low calorie, Mediterranean diet
Seems that weight loss corresponds better with benefit than diet. BMI reduction remains focus in PsA
Laura Coates #ACR25 meeting review @RheumNow https://t.co/CqR25sJdDc
David Liew drdavidliew ( View Tweet)
Impact on handedness in PsA disease activity and structural damage: a question that often comes in my practice
Comments on Abstract #1415 presented at #ACR25
https://t.co/GilOFvXajJ
@RheumNow
Aurelie Najm AurelieRheumo ( View Tweet)
#ACR25 Clinical Review by Prof Coates @DrLauraCoates to be applied tomorrow!
Early Diagnosis/Tx
Abstr#2689 EHR study = IL-17i could prevent #PsA vs IL-23/TNFi
Abstr#576 Oligo → Polyarthritis progression in women, no DMARD, enthesitis, dactylitis, nail psoriasis @RheumNow https://t.co/e1hCERpCNW
Links:
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Clinical Year in Preview
SpA: no difference in efficacy rotating vs switching bDMARD MoA for next steps
@RheumNow #ACR25 #LB09 https://t.co/shCLgk7Yqz
Jiha Lee JihaRheum ( View Tweet)
Do biologics prevent PsA?
Retro cohort analysis EHR through natural language processing
5 years trends
PsO treated w/ IL-17i had lower incidence of PsA/IA than pts treated w/ IL-23i, IL-12/23i, or TNFi therapies
Adjustment on several confounding
Prospective data heavily https://t.co/W9MFaWNbWC
Aurelie Najm AurelieRheumo ( View Tweet)
ACR25 coming to a close with Clinical Year in Preview
For PsA, can biologics prevent damage? If so, which one?
Difficult to answer often b/c confounding by indication. NLP-informed propensity matching beyond demographics for clinical factors like BSA
@RheumNow #ACR25 A#2689 https://t.co/jjpb0kTo34
Jiha Lee JihaRheum ( View Tweet)
#YearInPreview at #ACR25
@DrLauraCoates introduces the session with a teaser for work that will be presented later today.
Are we entering an era in which we will be able to prevent #PsA?
Find out more at 12:00 today, Abs #2689
@RheumNow https://t.co/GDTBGNTCCd
Mrinalini Dey DrMiniDey ( View Tweet)
The DIPSA study: can diet improve PsA?
Finally a RCT, and the general message is Loose weight, regardless of the diet!
3 arms:
-Mediterranean diet 31pts
-Low-calorie Dietary Approaches (DASH-LC) 30pts
-Standard of care 31pts
Primary outcome change in DAPSA wk 12
DASH-LC https://t.co/XH9Xdn0g96
Aurelie Najm AurelieRheumo ( View Tweet)
#ACR25 Abstr#LB20 At EULAR, data for Phase 3 RCT of Deucravacitinib, Tyk2-i in active #PsA showed ACR20 was met at WK16. Here, data showed sustained response through WK 52 across core domains inc. those who switched PBO->DEU. No major safety assoc. with JAK-i.A few acne @RheumNow https://t.co/tmzQMOtjev
Links:
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
POETYK PsA-1 (one of paired deucravacitinib in PsA ph3 registration studies)
Oral med
Good outcomes
Safety very good
but the bar is very high nowadays in PsA
Questions splicing through depth of response
Definitely will find a place in therapy, but where?
#ACR25 LB19 @RheumNow https://t.co/iqmHQrMTYN
Links:
David Liew drdavidliew ( View Tweet)
POETYK PsA 1 and 2 Deucravacitinib TYK2 inhibitor Ph3 RCT
52 wks data
Deucra 336pts PBO 334pts then crossover wk 16 to 52
Pooled analysis wk 16
ACR 20 54% vs. 31%
Enthesitis reduction LEI 52% vs. 45%
Dactylics resolution 58% vs. 44%
POETYK-PsA 1 Wk 52
ACR 20 63%
ACR50 44%
PASI https://t.co/LYJbU8fYwI
Links:
Aurelie Najm AurelieRheumo ( View Tweet)
In POETYK PsA-1, deucravacitinib showed sustained efficacy through Week 52 in PsA, improving joint, skin, PROs, and radiographic progression. Safety remained favorable with no new signals. TYK2 inhibition continues to show promise. Abstract#LB20 @RheumNow #ACR25 https://t.co/sGkk062HqJ
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Mease et al. 52 week results deucravacitinib in PsA. Approx ACR20 60%, ACR50 40%, ACR70 25%. Sustained radiographic benefit. No new safety signals @RheumNow #ACR25 Abstr#LB20 https://t.co/vKqjb08mI8
Richard Conway RichardPAConway ( View Tweet)
Secrets and Pearls in Rheumatology https://t.co/SwnlB8UbHO
@Janetbirdope pearls in rheumatology.
Sero negative inflammatory arthritis ? Or is it? Look at the toes for early signs of PsA.
In my clinic ITS inflammatory arthritis to determine etiology .
@RheumNow
#ACR25
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Secukinumab vs Ustekinumab in PsA https://t.co/EylYHtRWsj
@synovialjoints Elaborate more on head to head trial in PsA , in a population who failed TNF biologic.
@RheumNow
#ACR25
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
What's the latest in PsA? https://t.co/I8ZgRQpVy6
Great review for whats new in PsA by @drpnash
Looking forward for Large IL23-Axial study results.
@RheumNow
#ACR25
Links:
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Can we catch PsA before it starts?
My take on #ABSTRACT0877 for #ACR25
@RheumNow
https://t.co/Rw2gJ4XSsz
Aurelie Najm AurelieRheumo ( View Tweet)
Sleep Apnea in Psoriatic Arthritis – A Wake Up Call
Fatigue is one of the most disabling symptoms in psoriatic arthritis (PsA), yet its causes are often underexplored. At #ACR25, Abstract #0549, a possible hidden contributor was studied: obstructive sleep apnea (OSA). In a https://t.co/E3cy1Uss73
Dr. John Cush RheumNow ( View Tweet)
